Head to Head Survey: Flora Growth (NASDAQ:FLGC) versus NeurAxis (NASDAQ:NRXS)

NeurAxis (NASDAQ:NRXS – Get Free Report) and Flora Growth (NASDAQ:FLGC – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Valuation and Earnings

This table compares NeurAxis and Flora Growth”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NeurAxis $6.53 million 7.94 -$14.63 million ($1.06) -4.59
Flora Growth $57.61 million 0.05 -$15.91 million ($32.49) -0.09

NeurAxis has higher earnings, but lower revenue than Flora Growth. NeurAxis is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares NeurAxis and Flora Growth’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NeurAxis -492.76% N/A -641.25%
Flora Growth -32.03% -64.02% -34.46%

Risk and Volatility

NeurAxis has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500. Comparatively, Flora Growth has a beta of 1.9, meaning that its share price is 90% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for NeurAxis and Flora Growth, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NeurAxis 0 1 1 0 2.50
Flora Growth 1 0 0 0 1.00

NeurAxis currently has a consensus target price of $13.00, indicating a potential upside of 166.94%. Given NeurAxis’ stronger consensus rating and higher possible upside, equities analysts plainly believe NeurAxis is more favorable than Flora Growth.

Institutional & Insider Ownership

11.8% of NeurAxis shares are held by institutional investors. Comparatively, 36.0% of Flora Growth shares are held by institutional investors. 21.1% of NeurAxis shares are held by company insiders. Comparatively, 2.3% of Flora Growth shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

NeurAxis beats Flora Growth on 8 of the 14 factors compared between the two stocks.

About NeurAxis

(Get Free Report)

NeurAxis, Inc. is a medical technology company focused on developing neuromodulation therapies for chronic and functional pain conditions. Its approach uses percutaneous electrical nerve field stimulation (PENFS), which delivers mild electrical impulses through nerves associated with the brain-gut pathway. The company’s lead product, IB-Stim, is a wearable, minimally invasive device cleared by the U.S. Food and Drug Administration for use as an adjunctive treatment for functional abdominal pain associated with irritable bowel syndrome in patients ages 11 to 18 who have not responded to conventional therapy.

About Flora Growth

(Get Free Report)

Flora Growth Corp. is a cannabis and consumer wellness company with roots in Colombia. Founded in 2019, it initially focused on cultivating cannabis in the country and developing products for international markets. The company has since emphasized consumer brands and distribution, including hemp-derived CBD products sold under its JustCBD brand and accessories marketed through Vessel. Its products have been offered in markets including the United States and Europe, subject to local regulations. Flora Growth’s business has evolved from its original cultivation focus toward branded wellness products and international sales.

Receive News & Ratings for NeurAxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeurAxis and related companies with MarketBeat.com's FREE daily email newsletter.